Published in Breast Cancer Res on February 01, 2008
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell (2010) 6.47
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med (2013) 3.96
Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell (2008) 3.75
Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res (2010) 3.19
CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling. Oncogene (2011) 3.08
Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol (2012) 2.70
Targeting breast cancer stem cells. J Clin Oncol (2010) 2.53
Epigenetic regulation of SOX9 by the NF-κB signaling pathway in pancreatic cancer stem cells. Stem Cells (2013) 2.40
Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene (2011) 2.36
Nestin and other putative cancer stem cell markers in pancreatic cancer. Med Mol Morphol (2012) 2.21
Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst (2010) 1.89
Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One (2009) 1.82
Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A (2012) 1.80
Tumor size and survival in breast cancer--a reappraisal. Nat Rev Clin Oncol (2010) 1.70
In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am J Pathol (2010) 1.62
Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression. Neoplasia (2009) 1.60
Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Breast Cancer Res (2011) 1.57
Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res (2012) 1.55
Tissue-based identification of stem cells and epithelial-to-mesenchymal transition in breast cancer. Hum Pathol (2013) 1.50
Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB. J Transl Med (2009) 1.48
Doxycycline Induces Apoptosis and Inhibits Proliferation and Invasion of Human Cervical Carcinoma Stem Cells. PLoS One (2015) 1.44
The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. Cell Death Differ (2011) 1.44
The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res (2010) 1.44
c-Jun induces mammary epithelial cellular invasion and breast cancer stem cell expansion. J Biol Chem (2010) 1.40
Breast cancer stem cells: tools and models to rely on. BMC Cancer (2009) 1.38
Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival. PLoS One (2010) 1.35
Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv Mater (2011) 1.33
Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival. Mol Cancer (2010) 1.31
CD133 expression associated with poor prognosis in ovarian cancer. Mod Pathol (2011) 1.30
Integrins in mammary-stem-cell biology and breast-cancer progression--a role in cancer stem cells? J Cell Sci (2009) 1.27
High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant. Oncotarget (2015) 1.27
New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updat (2009) 1.27
Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation. Breast Cancer Res (2010) 1.26
Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Res (2008) 1.26
The stem cell marker CD133 associates with enhanced colony formation and cell motility in colorectal cancer. PLoS One (2010) 1.24
Generation of tumor-initiating cells by exogenous delivery of OCT4 transcription factor. Breast Cancer Res (2011) 1.24
Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. Br J Cancer (2010) 1.23
Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy. Mol Cancer (2009) 1.23
Nanotechnology-based molecular photoacoustic and photothermal flow cytometry platform for in-vivo detection and killing of circulating cancer stem cells. J Biophotonics (2009) 1.23
From bench to bedside: the growing use of translational research in cancer medicine. Am J Transl Res (2010) 1.22
Localization of CD44 and CD90 positive cells to the invasive front of breast tumors. Cytometry B Clin Cytom (2010) 1.21
Antibodies targeting cancer stem cells: a new paradigm in immunotherapy? MAbs (2010) 1.20
Nestin positively regulates the Wnt/β-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells. Breast Cancer Res (2014) 1.19
Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. J Transl Med (2011) 1.17
The role of breast cancer stem cells in metastasis and therapeutic implications. Am J Pathol (2011) 1.16
Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res (2013) 1.16
Functional heterogeneity within the CD44 high human breast cancer stem cell-like compartment reveals a gene signature predictive of distant metastasis. Mol Med (2012) 1.15
Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J Biol Chem (2011) 1.14
Epigenetic gene regulation in stem cells and correlation to cancer. Differentiation (2009) 1.11
Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice. Breast Cancer Res (2011) 1.10
Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implications. Langenbecks Arch Surg (2009) 1.10
Isolation of tumour stem-like cells from benign tumours. Br J Cancer (2009) 1.10
CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer. PLoS One (2012) 1.08
Role of oxidative stress in stem, cancer, and cancer stem cells. Cancers (Basel) (2010) 1.06
Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models. Stem Cells Transl Med (2013) 1.04
Cancer stem cell heterogeneity in hereditary breast cancer. Breast Cancer Res (2008) 1.04
Phenotypic heterogeneity of breast cancer stem cells. J Oncol (2011) 1.03
Tumor-initiating function of nucleostemin-enriched mammary tumor cells. Cancer Res (2010) 1.02
Recent insights into the molecular mechanisms involved in aging and the malignant transformation of adult stem/progenitor cells and their therapeutic implications. Ageing Res Rev (2008) 1.02
Dietary energy balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models. Cancer Prev Res (Phila) (2012) 1.01
Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells. Mol Cancer (2010) 1.01
A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity. Oncotarget (2014) 1.00
Phenotypic characterization of metastatic anaplastic thyroid cancer stem cells. PLoS One (2013) 1.00
Downregulation of CD44 reduces doxorubicin resistance of CD44CD24 breast cancer cells. Onco Targets Ther (2011) 1.00
New promising drug targets in cancer- and metastasis-initiating cells. Drug Discov Today (2010) 0.99
Chemopreventive effect of PSP through targeting of prostate cancer stem cell-like population. PLoS One (2011) 0.99
FOXC1 Activates Smoothened-Independent Hedgehog Signaling in Basal-like Breast Cancer. Cell Rep (2015) 0.98
Identification and characterization of cancer initiating cells from BRCA1 related mammary tumors using markers for normal mammary stem cells. Int J Biol Sci (2008) 0.98
ABC transporters in CSCs membranes as a novel target for treating tumor relapse. Front Pharmacol (2014) 0.98
Natural product inhibitors of Hsp90: potential leads for drug discovery. Mini Rev Med Chem (2009) 0.98
Lack of correlation of stem cell markers in breast cancer stem cells. Br J Cancer (2014) 0.97
Age determines the prognostic role of the cancer stem cell marker aldehyde dehydrogenase-1 in breast cancer. BMC Cancer (2012) 0.97
Wnt/β-catenin signaling plays an ever-expanding role in stem cell self-renewal, tumorigenesis and cancer chemoresistance. Genes Dis (2016) 0.97
Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma. PLoS One (2012) 0.96
Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cells. Mol Cancer (2010) 0.96
Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin). Cell Cycle (2012) 0.95
Statistical association of basal cell keratins with metastasis-inducing proteins in a prognostically unfavorable group of sporadic breast cancers. Am J Pathol (2011) 0.95
Therapy targets in glioblastoma and cancer stem cells: lessons from haematopoietic neoplasms. J Cell Mol Med (2013) 0.95
Glioma stem cell maintenance: the role of the microenvironment. Curr Pharm Des (2011) 0.93
New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence. Histol Histopathol (2010) 0.93
Co-expression of CXCR4 and CD133 proteins is associated with poor prognosis in stage II-III colon cancer patients. Exp Ther Med (2012) 0.93
Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1. Mol Cancer (2008) 0.93
Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer. Mol Cell Proteomics (2012) 0.93
New Findings on Breast Cancer Stem Cells: A Review. J Breast Cancer (2015) 0.92
Genome and transcriptome profiles of CD133-positive colorectal cancer cells. Am J Pathol (2011) 0.92
The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies. Oncologist (2012) 0.92
Delineation of breast cancer cell hierarchy identifies the subset responsible for dormancy. Sci Rep (2012) 0.92
"A novel in vivo model for the study of human breast cancer metastasis using primary breast tumor-initiating cells from patient biopsies". BMC Cancer (2012) 0.92
Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer. Biomed Res Int (2015) 0.91
Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer. Mol Cancer Ther (2011) 0.91
Role of COX-2 in tumorospheres derived from a breast cancer cell line. J Surg Res (2010) 0.91
Significance of CD133 as a cancer stem cell markers focusing on the tumorigenicity of pancreatic cancer cell lines. J Korean Surg Soc (2011) 0.91
Characterization of aldehyde dehydrogenase isozymes in ovarian cancer tissues and sphere cultures. BMC Cancer (2012) 0.91
Tumorsphere as an effective in vitro platform for screening anti-cancer stem cell drugs. Oncotarget (2016) 0.91
Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers. Breast Cancer Res Treat (2013) 0.91
Highly specific role of the insulin receptor in breast cancer progression. Endocr Relat Cancer (2015) 0.90
Relationship of CD44+CD24-/low breast cancer stem cells and axillary lymph node metastasis. J Transl Med (2012) 0.90
Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Gynecol Oncol (2013) 0.90
Molecular biomarkers of cancer stem/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancers. Cancer Epidemiol Biomarkers Prev (2013) 0.89
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (1994) 36.53
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science (2003) 13.19
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
BRCA1 mutations in primary breast and ovarian carcinomas. Science (1994) 6.81
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst (2000) 6.38
CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res (2005) 4.79
Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci U S A (2003) 4.69
Steroid hormone receptor status of mouse mammary stem cells. J Natl Cancer Inst (2006) 4.47
Isolation of neural stem cells from the postnatal cerebellum. Nat Neurosci (2005) 3.97
Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells (2007) 3.60
Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood (2005) 3.51
BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res (2006) 3.29
Enrichment of a population of mammary gland cells that form mammospheres and have in vivo repopulating activity. Cancer Res (2007) 3.04
Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer (2005) 2.89
CD44 in cancer. Crit Rev Clin Lab Sci (2002) 2.83
Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet (2001) 2.82
Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. Oncogene (2006) 2.25
The hedgehog signaling pathway in cancer. Clin Cancer Res (2006) 2.15
Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene (1999) 2.09
Relevance of DNA methylation in the management of cancer. Lancet Oncol (2003) 1.97
The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol Cancer Res (2005) 1.93
Inhibition of hsp90 compromises the DNA damage response to radiation. Cancer Res (2006) 1.68
In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol (2005) 1.60
Tumour-initiating cells vs. cancer 'stem' cells and CD133: what's in the name? Biochem Biophys Res Commun (2007) 1.57
Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells. Stem Cells (2007) 1.53
Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Clin Cancer Res (2004) 1.23
Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models. Clin Cancer Res (2007) 1.22
Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines. Clin Cancer Res (2006) 1.12
Plasma membrane calcium ATPase (PMCA4): a housekeeper for RT-PCR relative quantification of polytopic membrane proteins. BMC Mol Biol (2006) 1.11
Discovery and development of pyrazole-scaffold Hsp90 inhibitors. Curr Top Med Chem (2006) 1.10
A role of estrogen/ERalpha signaling in BRCA1-associated tissue-specific tumor formation. Oncogene (2007) 1.10
RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Biochem Biophys Res Commun (2006) 1.09
Cancer stem cells--an old idea that's new again: implications for the diagnosis and treatment of breast cancer. Expert Opin Biol Ther (2007) 1.04
Mutations in the BRCA1 gene in Japanese breast cancer patients. Hum Mutat (1996) 1.01
A self-renewal assay for cancer stem cells. Cancer Chemother Pharmacol (2005) 0.99
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents. Int J Oncol (2005) 0.98
Novel somatic mutations in the BRCA1 gene in sporadic breast tumors. Hum Mutat (2005) 0.95
Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1. Mol Cancer (2008) 0.93
Identification of murine mammary stem cells: implications for studies of mammary development and carcinogenesis. Breast Cancer Res (2006) 0.91
Harnessing genetically engineered mouse models for preclinical testing. Chem Biol Interact (2007) 0.91
New perspectives for cancer chemotherapy by genetic protection of haematopoietic cells. Expert Rev Mol Med (1999) 0.83
A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science (2006) 15.18
The knockout mouse project. Nat Genet (2004) 7.80
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A (2009) 2.35
The chaperone-mediated autophagy receptor organizes in dynamic protein complexes at the lysosomal membrane. Mol Cell Biol (2008) 2.33
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest (2010) 2.32
A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med (2009) 2.27
Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res (2007) 2.26
Chaperone-mediated autophagy is required for tumor growth. Sci Transl Med (2011) 2.21
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res (2007) 2.15
microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. Blood (2008) 2.10
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res (2008) 2.04
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res (2007) 1.91
Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst (2010) 1.89
Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Mol Cancer Ther (2009) 1.83
Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima. J Mol Biol (2008) 1.80
Microenvironmental modulation of asymmetric cell division in human lung cancer cells. Proc Natl Acad Sci U S A (2010) 1.66
Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res (2006) 1.64
Silent (synonymous) SNPs: should we care about them? Methods Mol Biol (2009) 1.61
Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res (2010) 1.55
VAMP2-dependent exocytosis regulates plasma membrane insertion of TRPC3 channels and contributes to agonist-stimulated Ca2+ influx. Mol Cell (2004) 1.49
Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones. Nutr Cancer (2008) 1.49
The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci (2010) 1.46
Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol (2008) 1.46
Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos (2008) 1.46
The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. Biochemistry (2006) 1.45
The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. Cancer Res (2005) 1.42
Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos (2010) 1.41
Functional characterization of Candida albicans ABC transporter Cdr1p. Eukaryot Cell (2003) 1.40
Catalytic cycle of ATP hydrolysis by P-glycoprotein: evidence for formation of the E.S reaction intermediate with ATP-gamma-S, a nonhydrolyzable analogue of ATP. Biochemistry (2007) 1.35
Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol (2002) 1.35
Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res (2011) 1.34
Human ABCB6 localizes to both the outer mitochondrial membrane and the plasma membrane. Biochemistry (2007) 1.33
Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin Drug Metab Toxicol (2008) 1.32
Mutational analysis of ABCG2: role of the GXXXG motif. Biochemistry (2004) 1.29
About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work. Mol Cancer Ther (2007) 1.27
Importance of the conserved Walker B glutamate residues, 556 and 1201, for the completion of the catalytic cycle of ATP hydrolysis by human P-glycoprotein (ABCB1). Biochemistry (2002) 1.20
Identification of carboxypeptidase E and gamma-glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors by cDNA microarray. Hum Pathol (2004) 1.20
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol (2007) 1.19
Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1. Cancer Res (2007) 1.19
The obesity-cancer link: lessons learned from a fatless mouse. Cancer Res (2007) 1.19
Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex. Drug Metab Dispos (2013) 1.18
ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions. Curr Drug Deliv (2007) 1.18
New inhibitors of ABCG2 identified by high-throughput screening. Mol Cancer Ther (2007) 1.18
Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol Cell Biochem (2006) 1.16
Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res (2010) 1.16
The sounds of silence: synonymous mutations affect function. Pharmacogenomics (2007) 1.14
Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Mol Cancer Ther (2006) 1.14
Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter. Mol Cancer Ther (2007) 1.13
HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. Mol Cancer Ther (2008) 1.13
Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. Drug Resist Updat (2012) 1.12
Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol (2008) 1.12
Evidence for the role of glycosylation in accessibility of the extracellular domains of human MRP1 (ABCC1). Biochemistry (2002) 1.12
Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines. Clin Cancer Res (2006) 1.12
Plasma membrane calcium ATPase (PMCA4): a housekeeper for RT-PCR relative quantification of polytopic membrane proteins. BMC Mol Biol (2006) 1.11
The molecular basis of the action of disulfiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1). Mol Pharmacol (2004) 1.11
Disulfiram, an old drug with new potential therapeutic uses for human cancers and fungal infections. Mol Biosyst (2005) 1.10
Studies with novel Pdr5p substrates demonstrate a strong size dependence for xenobiotic efflux. J Biol Chem (2002) 1.08
Multidrug resistance protein 4 (ABCC4)-mediated ATP hydrolysis: effect of transport substrates and characterization of the post-hydrolysis transition state. J Biol Chem (2004) 1.07
Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation. Cancer Res (2006) 1.06
Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. Mol Pharm (2011) 1.06
Botryllamides: natural product inhibitors of ABCG2. ACS Chem Biol (2009) 1.05
Use of baculovirus BacMam vectors for expression of ABC drug transporters in mammalian cells. Drug Metab Dispos (2011) 1.05
Structure of a multidrug transporter. Nat Biotechnol (2009) 1.04
The yeast Pdr5p multidrug transporter: how does it recognize so many substrates? Biochem Biophys Res Commun (2007) 1.04
MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer. Cancer Res (2013) 1.04
Opposing effect of angiopoietin-1 on VEGF-mediated disruption of endothelial cell-cell interactions requires activation of PKC beta. J Cell Physiol (2004) 1.04
Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J (2005) 1.04
The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. Cancer Res (2010) 1.04
Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res (2008) 1.03
The glucose-6-phosphate transporter is a phosphate-linked antiporter deficient in glycogen storage disease type Ib and Ic. FASEB J (2008) 1.03
The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther (2012) 1.03
Complete inhibition of the Pdr5p multidrug efflux pump ATPase activity by its transport substrate clotrimazole suggests that GTP as well as ATP may be used as an energy source. Biochemistry (2007) 1.02
Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure. Mol Cancer Ther (2007) 1.02
Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol (2011) 1.02
A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase. Mol Cell Biol (2004) 1.02
Dietary energy balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models. Cancer Prev Res (Phila) (2012) 1.01
The conserved tyrosine residues 401 and 1044 in ATP sites of human P-glycoprotein are critical for ATP binding and hydrolysis: evidence for a conserved subdomain, the A-loop in the ATP-binding cassette. Biochemistry (2006) 1.01
Exploiting reaction intermediates of the ATPase reaction to elucidate the mechanism of transport by P-glycoprotein (ABCB1). J Biol Chem (2006) 1.01
Genomics and the mechanism of P-glycoprotein (ABCB1). J Bioenerg Biomembr (2007) 1.00
Mechanisms by which cAMP increases bile acid secretion in rat liver and canalicular membrane vesicles. Am J Physiol Gastrointest Liver Physiol (2003) 0.98
The signaling interface of the yeast multidrug transporter Pdr5 adopts a cis conformation, and there are functional overlap and equivalence of the deviant and canonical Q-loop residues. Biochemistry (2010) 0.96
Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2. Proc Natl Acad Sci U S A (2013) 0.96
Biochemical basis of polyvalency as a strategy for enhancing the efficacy of P-glycoprotein (ABCB1) modulators: stipiamide homodimers separated with defined-length spacers reverse drug efflux with greater efficacy. Biochemistry (2004) 0.95
The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. PLoS One (2011) 0.95
Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer. Cell Cycle (2011) 0.95
Curcumin modulates efflux mediated by yeast ABC multidrug transporters and is synergistic with antifungals. Antimicrob Agents Chemother (2009) 0.94
The role of hydrogen bond acceptor groups in the interaction of substrates with Pdr5p, a major yeast drug transporter. Biochemistry (2005) 0.94
Curcuminoids purified from turmeric powder modulate the function of human multidrug resistance protein 1 (ABCC1). Cancer Chemother Pharmacol (2005) 0.94